AIM: To examine whether and how rosiglitazone enhances apoptosis induced by fluorouracil in human colon cancer (HT-29) cells. METHODS: Human colon cancer HT-29 cells were cultured in vitro and treated with fluorouracil and/or rosiglitazone. Proliferation and growth of HT-29 cells were evaluated by MTT assay and trypan blue exclusion methods, respectively. The apoptosis of HT-29 cells was determined by acridine orange/ethidium bromide staining and flow cytometry using PI fluorescence staining. The expressions of peroxisome proliferator-activated receptor gamma (PPARgamma), Bcl-2 and Bax in HT-29 cells were analyzed by Western blot. RESULTS: Although rosiglitazone at the concentration below 30 micromol/L for 72 h exerted almost no inhibitory effect on proliferation and growth of HT-29 cells, it could significantly enhance fluorouracil-induced HT-29 cell proliferation and growth inhibition. Furthermore, 10 micromol/L rosilitazone did not induce apoptosis of HT-29 cells but dramatically enhanced fluorouracil-induced apoptosis of HT-29 cells. However, rosiglitazone did not improve apoptosis induced by fluorouracil in HT-29 cells pretreated with GW9662, a PPARgamma antagonist. Meanwhile, the expression of Bax and PPARgamma was up-regulated, while the expression of Bcl-2 was down regulated in HT-29 cells treated with rosiglitazone in a time-dependent manner. However, the effect of rosiglitazone on Bcl-2 and Bax was blocked or diminished in the presence of GW9662. CONCLUSION: Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating PPARgamma.
AIM: To examine whether and how rosiglitazone enhances apoptosis induced by fluorouracil in humancolon cancer (HT-29) cells. METHODS:Humancolon cancer HT-29 cells were cultured in vitro and treated with fluorouracil and/or rosiglitazone. Proliferation and growth of HT-29 cells were evaluated by MTT assay and trypan blue exclusion methods, respectively. The apoptosis of HT-29 cells was determined by acridine orange/ethidium bromide staining and flow cytometry using PI fluorescence staining. The expressions of peroxisome proliferator-activated receptor gamma (PPARgamma), Bcl-2 and Bax in HT-29 cells were analyzed by Western blot. RESULTS: Although rosiglitazone at the concentration below 30 micromol/L for 72 h exerted almost no inhibitory effect on proliferation and growth of HT-29 cells, it could significantly enhance fluorouracil-induced HT-29 cell proliferation and growth inhibition. Furthermore, 10 micromol/L rosilitazone did not induce apoptosis of HT-29 cells but dramatically enhanced fluorouracil-induced apoptosis of HT-29 cells. However, rosiglitazone did not improve apoptosis induced by fluorouracil in HT-29 cells pretreated with GW9662, a PPARgamma antagonist. Meanwhile, the expression of Bax and PPARgamma was up-regulated, while the expression of Bcl-2 was down regulated in HT-29 cells treated with rosiglitazone in a time-dependent manner. However, the effect of rosiglitazone on Bcl-2 and Bax was blocked or diminished in the presence of GW9662. CONCLUSION:Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating PPARgamma.
Authors: Rupert P Austin; Patrick Barton; Scott L Cockroft; Mark C Wenlock; Robert J Riley Journal: Drug Metab Dispos Date: 2002-12 Impact factor: 3.922
Authors: H Sultana; J Kigawa; Y Kanamori; H Itamochi; T Oishi; S Sato; S Kamazawa; M Ohwada; M Suzuki; N Terakawa Journal: Ann Oncol Date: 2003-02 Impact factor: 32.976
Authors: Y Hashimoto; Y Shimada; A Itami; T Ito; J Kawamura; A Kawabe; J Kaganoi; M Maeda; G Watanabe; M Imamura Journal: Eur J Cancer Date: 2003-10 Impact factor: 9.162
Authors: Stephanie K Bunt; Ashley M Mohr; Jennifer M Bailey; Paul M Grandgenett; Michael A Hollingsworth Journal: Cancer Immunol Immunother Date: 2012-08-05 Impact factor: 6.968
Authors: Julie Rageul; Stéphanie Mottier; Anne Jarry; Yatrik Shah; Sandrine Théoleyre; Damien Masson; Frank J Gonzalez; Christian L Laboisse; Marc G Denis Journal: Int J Cancer Date: 2009-12-15 Impact factor: 7.396